Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTarsus Regulatory News (TRS)

  • There is currently no data for TRS

Trading Statement

3 Oct 2011 07:00

RNS Number : 3414P
Tarsus Group PLC
03 October 2011
 



Tarsus Group plc

3 October 2011

Disposal of French Joint Venture

and

Trading Update

Modamont - France

 

Tarsus Group plc ('Tarsus', the 'Group' or the 'Company'), the international business-to-business media group, is pleased to announce that it has reached agreement to dispose of its 51 per cent. interest in the joint venture, Modamont SAS ("Modamont"), to its joint venture partner, Premiere Vision SAS, for a total consideration of €6.1 million (the "Disposal").

 

Modamont is the leading exhibition for fashion accessories in France and takes place bi-annually in Paris in February and September. In the year ended 31 December 2010 Tarsus's 51 per cent. share of Modamont revenues and profits were approximately €2.2 million and €0.6 million respectively. Tarsus's share of Modamont's net assets were approximately €0.7 million as at 30 September 2011. Tarsus's share of Modamont's gross assets as at 30 June 2011 were approximately €1.5 million. At completion, Tarsus France SAS will repay a loan of €2.2 million to Modamont. The net proceeds from the Disposal will be used to give additional flexibility to the Company's balance sheet.

 

Owing to its significant shareholding in Modamont, Premiere Vision is considered to be a related party for the purposes of the Listing Rules and the Disposal therefore constitutes a related party transaction. Consequently, the Disposal is subject to and conditional upon the approval of shareholders in the Company at a general meeting. Further details of the Disposal and a notice convening a general meeting to approve the Disposal will be sent to Tarsus shareholders in due course.

 

Trading Update

 

Since the announcement of the Group's interim results on 27 July 2011, the Group has held three major exhibitions. Off Price took place in Las Vegas in August 2011 and generated a like-for-like revenue increase of approximately 6 per cent. Modamont and Labelexpo Europe (the second largest show in the Group's portfolio, held in Brussels) both took place in September and produced like-for-like revenue increases of 9 per cent. and over 10 per cent. respectively, both slightly ahead of management's expectations. The Group's largest event in the fourth quarter, the Dubai Airshow, is on track to meet management's expectations.

 

Forward bookings continue to be strong and the Board is increasingly confident of good progress being made this year.

 

Douglas Emslie, Group Managing Director of Tarsus, commented:

 

"The disposal of Modamont will materially reduce our exposure to the lower growth European market and less than 10 per cent. of Group profits will now be generated from France. Tarsus France will continue to focus on its remaining wholly owned portfolio of exhibitions.

 

We now have greater financial flexibility to accelerate our drive into the faster growth emerging markets where we are actively pursuing potential acquisitions. As we continue to execute our growth strategy we anticipate a further significant increase in the proportion of our business coming from the emerging markets".

 

For further information, please contact:

 

Tarsus Group plc:

 

Douglas Emslie, Group Managing Director 020 8846 2700

Dan O'Brien, Group Finance Director 020 8846 2700

 

Media

Madano Partnership:

Matthew Moth 020 7593 4000

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTUROSRAVAKOAR
Date   Source Headline
8th Dec 20164:35 pmRNSHolding(s) in Company
8th Dec 20164:33 pmRNSHolding(s) in Company
8th Dec 20164:31 pmRNSHolding(s) in Company
8th Dec 20164:29 pmRNSHolding(s) in Company
8th Dec 20167:00 amRNSCompletion of Acquisition
7th Dec 20169:00 amRNSAdmission of Placing Shares
5th Dec 201612:30 pmRNSCompletion of Placing
5th Dec 20167:00 amRNSProposed Placing and Acquisition
1st Dec 201610:46 amRNSTotal Voting Rights
22nd Nov 20167:00 amRNSCapital Markets Event and Trading Update
9th Nov 20163:19 pmRNSBlock listing Interim Review
31st Oct 20169:52 amRNSTotal Voting Rights
13th Oct 20167:24 amRNSDirector/PDMR Shareholding
12th Oct 20167:00 amRNSTrading Update
30th Sep 20169:53 amRNSTotal Voting Rights and Capital
1st Sep 201612:09 pmRNSTotal Voting Rights
15th Aug 20165:28 pmRNSInterim financial statements
9th Aug 20166:11 pmRNSHolding(s) in Company
29th Jul 201612:10 pmRNSTotal Voting Rights and Capital
27th Jul 20167:00 amRNSHalf-year Report
11th Jul 20161:30 pmRNSApplication for Admission
5th Jul 20161:12 pmRNSHolding(s) in Company
30th Jun 201612:28 pmRNSTotal Voting Rights
21st Jun 20164:42 pmRNSDirector/PDMR Shareholding
20th Jun 20164:00 pmRNSResult of AGM
7th Jun 20161:15 pmRNSDirector/PDMR Shareholding
3rd Jun 20162:58 pmRNSScrip Dividend Circular (the "Circular")
31st May 201611:59 amRNSTotal Voting Rights and Capital
17th May 20163:08 pmRNSNotice of 2016 Annual General Meeting
17th May 20167:00 amRNSTrading Update
11th May 20167:00 amRNSDirector/PDMR Shareholding
9th May 20163:43 pmRNSBlock Listing Six Monthly Return
29th Apr 20164:14 pmRNSTotal Voting Rights
31st Mar 20162:25 pmRNSTotal Voting Rights
31st Mar 20162:24 pmRNSDirector/PDMR Shareholding
21st Mar 20163:11 pmRNS2015 Annual Report
8th Mar 20165:55 pmRNSDirector/PDMR Shareholding
3rd Mar 20164:47 pmRNSDirector/PDMR Shareholding
2nd Mar 20167:00 amRNSFinal Results
2nd Feb 20163:48 pmRNSTotal Voting Rights and Capital
25th Jan 20161:05 pmRNSApplication for Admission
12th Jan 20167:00 amRNSYear-end trading update
31st Dec 20159:25 amRNSTotal Voting Rights
14th Dec 20155:07 pmRNSScrip dividend circular
8th Dec 20157:00 amRNSCapital markets presentation
2nd Dec 20153:49 pmRNSDirector/PDMR Shareholding
30th Nov 20154:35 pmRNSTotal Voting Rights
11th Nov 201510:00 amRNSBlock Listing Six Monthly Return
30th Oct 20153:22 pmRNSDirector/PDMR Shareholding
30th Oct 20153:20 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.